Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

ucb-pharma sa - bimekizumabum - soluzione iniettabile en seringue préremplie - bimekizumabum 160 mg, glycinum, natrii acetas trihydricus, acidum aceticum glaciale, polysorbatum 80, aqua ad iniectabile, ad solutionem pro 1.0 ml corresp., natrium 0.45 mg. - psoriasis en plaques chez l'adulte - biotechnologika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

ucb-pharma sa - bimekizumabum - soluzione per iniezione in pre-riempita penna - bimekizumabum 160 mg, glycinum, natrii acetas trihydricus, acidum aceticum glaciale, polysorbatum 80, aqua ad iniectabile, ad solutionem pro 1.0 ml corresp., natrium 0.45 mg. - psoriasis en plaques chez l'adulte - biotechnologika

Unione Europea - italiano - EMA (European Medicines Agency)

ucb pharma s.a.   - bimekizumab - psoriasi - immunosoppressori - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - bevacizumabum - concentrato per soluzione per infusione - bevacizumabum 100 mg, trehalosum dihydricum, natrii dihydrogenophosphas monohydricus, dinatrii phosphas, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 4 ml corresp. natrium 5.416 mg. - metastasiertes del colon o del retto; metastasiertes carcinoma della mammella; avanzato, metastasiertes o rezidivierendes non-tumori polmonari a piccole carcinoma polmonare (nsclc); avanzato e/o metastasierendes carcinoma a cellule renali; glioblastoma (oms grado iv); il tumore ovarico, eileiterkarzinom, primario peritonealkarzinom; carcinoma della cervice - biotechnologika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - bevacizumabum - concentrato per soluzione per infusione - bevacizumabum 400 mg, trehalosum dihydricum, natrii dihydrogenophosphas monohydricus, dinatrii phosphas, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 16 ml corresp. natrium 21.664 mg. - metastasiertes del colon o del retto; metastasiertes carcinoma della mammella; avanzato, metastasiertes o rezidivierendes non-tumori polmonari a piccole carcinoma polmonare (nsclc); avanzato e/o metastasierendes carcinoma a cellule renali; glioblastoma (oms grado iv); il tumore ovarico, eileiterkarzinom, primario peritonealkarzinom; carcinoma della cervice - biotechnologika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - bevacizumabum - concentrato per soluzione per infusione - bevacizumabum 100 mg, acidum succinicum, saccharum, dinatrii edetas, polysorbatum 80, natrii hydroxidum, aqua ad iniectabile q.s. ad solutionem pro 4 ml corresp. natrium 2.32 mg. - onkologikum - biotechnologika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - bevacizumabum - concentrato per soluzione per infusione - bevacizumabum 400 mg, acidum succinicum, saccharum, dinatrii edetas, polysorbatum 80, natrii hydroxidum, aqua ad iniectabile q.s. ad solutionem pro 16 ml corresp. natrium 9.29 mg. - onkologikum - biotechnologika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

spirig healthcare ag - bevacizumabum - concentrato per soluzione per infusione - bevacizumabum 100 mg, trehalosum dihydricum, natrii dihydrogenophosphas monohydricus, dinatrii phosphas, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 4 ml corresp. natrium 5.42 mg. - metastasiertes kolon- oder rektumkarzinom, metastasiertes mammakarzinom, fortgeschrittenes, metastasiertes oder rezidivierendes nicht-kleinzelliges lungenkarzinom (nsclc), fortgeschrittenes und/oder metastasierendes nierenzellkarzinom, glioblastom (who grad iv), ovarialkarzinom, zervixkarzinom - biotechnologika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

spirig healthcare ag - bevacizumabum - concentrato per soluzione per infusione - bevacizumabum 400 mg, trehalosum dihydricum, natrii dihydrogenophosphas monohydricus, dinatrii phosphas, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 16 ml corresp. natrium 21.68 mg. - metastasiertes kolon- oder rektumkarzinom, metastasiertes mammakarzinom, fortgeschrittenes, metastasiertes oder rezidivierendes nicht-kleinzelliges lungenkarzinom (nsclc), fortgeschrittenes und/oder metastasierendes nierenzellkarzinom, glioblastom (who grad iv), ovarialkarzinom, zervixkarzinom - biotechnologika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

eli lilly (suisse) sa - ixekizumabum - soluzione iniettabile en seringue préremplie - ixekizumabum 80 mg, saccharum, polysorbatum 80, natrii hydroxidum q.s. ad ph, aqua ad iniectabile, ad solutionem pro 1 ml. - psoriasis en plaques chez l'adulte, arthrite psoriasique, psoriasis en plaques chez l'enfant et l'adolescent à partir de 6 ans et d'un poids corporel d'au moins 25 kg, spondylarthrite ankylosante, spondyloarthrite axiale non radiographique - biotechnologika